Fate Therapeutics Overview
Fate Therapeutics Target Price
Analysts' 12-month price predictions for FATE.
Get informed when a big investor buys or sells
+ FollowShare Price
$2.22
Average Target Price
$4.00
80.2% upside
80.2% upside1 analysts in the last 4 months
High: $4 | Low: $4
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-05-19 | Jefferies | $4 | 80.2% upside |  |
| 2025-03-06 | Stifel Nicolaus | $3 | 35.1% upside | |
| 2024-11-13 | BMO CapitalEtzer Darout | $5 | 125.2% upside | |
| 2024-08-14 | Stifel NicolausBenjamin Burnett | $5 | 125.2% upside | |
| 2024-06-17 | Piper SandlerEdward Tenthoff | $6 | 170.3% upside | |
| 2024-05-16 | H.C. WainwrightDebjit Chattopadhyay | $5 | 125.2% upside | |
| 2024-05-10 | Piper SandlerEdward Tenthoff | $4 | 80.2% upside | |
| 2024-05-10 | BMO CapitalEtzer Darout | $6 | 170.3% upside | |
| 2024-05-10 | Canaccord GenuityBill Maughan | $9 | 305.4% upside | |
| 2023-01-09 | Goldman Sachs | $4 | 80.2% upside | |
| 2023-01-06 | Morgan Stanley | $8 | 260.4% upside | |
| 2023-01-06 | Piper Sandler | $12 | 440.5% upside | |
| 2023-01-06 | BMO Capital | $7 | 215.3% upside | |
| 2023-01-05 | Truist FinancialRobyn Karnauskas | $7 | 215.3% upside | |
| 2022-12-15 | Goldman SachsAndrea Tan | $10 | 350.5% upside | |
| 2022-12-13 | Truist Financial | $46 | 1972.1% upside | |
| 2021-12-13 | OppenheimerMatthew Biegler | $135 | 5981.1% upside | |
| 2021-11-08 | CitigroupYigal Nochomovitz | $87 | 3818.9% upside | |
| 2021-11-05 | Roth CapitalAnthony Butler | $60 | 2602.7% upside | |
| 2021-10-25 | JefferiesMichael Yee | $145 | 6431.5% upside | |
| 2021-08-20 | Piper SandlerEdward Tenthoff | $113 | 4990.1% upside | |